A Case of Nephrotic Syndrome Induced by FOLFIRI plus Ramucirumab for Metastatic Descending Colon Cancer

We report a case of multiple lung metastases of RAS mutant type descending colon cancer with development of nephrotic syndrome after the introduction of FOLFIRI plus ramucirumab(RAM). A female patient in her 50s underwent adjuvant chemotherapy with capecitabine and oxaliplatin after primary tumor an...

Full description

Saved in:
Bibliographic Details
Published inGan to kagaku ryoho Vol. 46; no. 13; p. 2155
Main Authors Shingai, Tatsushi, Fukuzaki, Takayuki, Okimura, Shumpei, Ito, Yoshiro, Taniguchi, Yoshiki, Fukata, Tadafumi, Nishida, Hisashi, Takayama, Osamu, Yoshioka, Setsuko, Hojo, Shigeyuki, Ohigashi, Hiroaki
Format Journal Article
LanguageJapanese
Published Japan 01.12.2019
Subjects
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bevacizumab
Camptothecin
Colon, Descending
Colorectal Neoplasms
Female
Fluorouracil
Humans
Leucovorin
Middle Aged
Nephrotic Syndrome - chemically induced
Ramucirumab
Online AccessGet more information

Cover

More Information
Summary:We report a case of multiple lung metastases of RAS mutant type descending colon cancer with development of nephrotic syndrome after the introduction of FOLFIRI plus ramucirumab(RAM). A female patient in her 50s underwent adjuvant chemotherapy with capecitabine and oxaliplatin after primary tumor and partial lung resection. For recurrent multiple lung metastases, 4 years of capecitabine and bevacizumab therapy was administered. FOLFIRI plus RAM therapy was introduced because of tumor progression. After treatment, the patient showed increased urine protein content, decreased serum albumin levels, marked hypertension, and increased edema, and was diagnosed with nephrotic syndrome. The patient's condition improved with prednisolone, additional doses of antihypertensive, and diuretics. Even in cases where it is possible to control proteinuria during bevacizumab administration, it is necessary to keep in mind that RAM administration as second-line therapy may cause nephrotic syndrome.
ISSN:0385-0684